|Volume 25 | Issue 3|
|From the President’s Desk by John Rasko, AO, BSc(Med), MBBS(Hons), PhD, MAICD, FFSc(RCPA), FRCPA, FRACP, FAHMS|
|I am writing my first Telegraft as the newly installed President following an incredibly successful and record breaking annual meeting in Montréal. This is the first time an ISCT President has been writing from the southern hemisphere and I’m happy to advise that the Society’s gavel is well protected in my office Down Under! I had no idea that the actual physical passing of the gavel in the transition during the AGM led to its possession through the duration of the Presidency. Its bronze plaque records “Presidential Gavel: International Society for Hematotherapy and Graft Engineering” in recognition of our Society’s origins … back in the ISHAGE! I thank Cath Bollard for giving the symbol of the Presidency an especial polish before handing it over, just as our Society is polished and ready for a bright future. |
| In case you missed it… Recap from the ISCT 2018 Annual Meeting in Montréal, Canada! |
For those unable to attend the May ISCT 2018 Annual Meeting in gorgeous Montréal and for those who were overwhelmed by the multiple concurrent options at the event, here are some highlights emphasizing vibrant growth of the cell therapy fields and ISCT’s key position in many scientific and clinical advances. We had record-breaking attendance at the main meeting – 1602 participants from 53 countries.
The ISCT 2018 Organizing Committee
|Presentation by Stanley Riddell, MD during the Presidential Plenary on Cancer Immunotherapy |
ISCT Commercialization Committee – Logistics Session Summary presented in the Strategies for Commercialization Track
Future proofing your supply chain; using the lessons of the past to create commercially viable logistics platforms for the future
This session used MACI, Strimvelis and Provenge as applied examples, then overlaid the broader view of a CMO to identify lessons learned and suggest what supply chains of the future should look like.
ISCT In the News
Telegraft Live from ISCT 2018 Montreal
ISCT 2018: highlights in brief (as reported by RegMedNet)
“Facing the Good Problems” Featuring Denis-Claude Roy, ISCT 2018 Co-Chair – The Medicine Maker
“FDA Quackdown” Featuring Massimo Dominici, ISCT Past President 2014 – 2016 – The Medicine Maker
“Gene therapy gathers pace” Featuring John Rasko, ISCT President and Miguel Forte, ISCT CCO – Chemistry World
“Industry keeps faith in finding solutions to bring stem cell and gene therapies to the masses” Interview with Catherine Bollard, ISCT Immediate Past President & Bruce Levine, ISCT President-Elect – The Pharma Letter
Click here to view more ISCT in the News
|New ISCT Name and Logo Unveiled |
On Thursday, May 3 during the Opening Remarks at the ISCT 2018 Annual Meeting in Montréal, Canada, ISCT President Catherine Bollard, MBChB, MD unveiled the new logo and name of the Society: International Society for Cell & Gene Therapy. This new name and logo reflects the expanded scope of ISCT to formally include both cell and gene therapy.
|Catherine Bollard, MBChB, MD|
ISCT President 2016-2018
Nancy H. Collins, PhD receiving the ISCT 2018 Career Achievement Award
L to R: Adrian Gee, Catherine Bollard, Nancy Collins, Daniel Weiss, Shelly Heimfeld
|Tribute to Nancy H. Collins, 2018 ISCT Career Achievement Award Recipientby Carolyn A. Keever-Taylor, PhD|
The ISCT Career Achievement Award was created in 2016 to honor individuals who have made significant contributions to the field of cellular therapy, including to ISCT itself. ISCT recognizes that the field of cellular therapy depends upon multiple contributing sources, including academia, regulatory affairs (including quality operations), and industry.
|Catch up with the ISCT Industry Community|
The ISCT Industry Community has had a busy first half of 2018! Most recently, a summary of the 2018 Commercialization Signature Series (Jan 2018, Miami) was published in BioInsights. For a complete update on the activities of the first six months of 2018 from the ISCT industry community, read the mid-year update here.
Extra Time to Save $100 – Register Now!
EXTENDED Early Registration Deadline: June 29
|Special ISCT Membership Promo – Save 25% for 2019 |
ALL ISCT EU 2018 Regional Meeting delegates receive 25% off
*not available for resident/fellow or countries eligible for reduced rate membership categories
Program Available Online
ISCT Cytotherapy Senior Editor Search – Call out for Applications
The International Society for Cell & Gene Therapy (ISCT) is seeking a Senior Editor for the Society’s official peer-reviewed journal, Cytotherapy. The position is slated to begin in September 2018. The journal addresses the latest developments in the fast-moving field of cellular and gene therapy in man.
Click here to view the posting
Bruce Levine, PhD
|ISCT ESP Corner – CGT Profiles with Bruce Levine, PhD|
With the announcement of the ISCT Election winners at the Annual Meeting in Montreal and the announcement of ISCT’s President-Elect, we decided to have a short conversation with Bruce Levine on his career path, advice to young professionals, and plans for active involvement of the ESPs within our community.
BioInsights – Bruce Levine, ISCT President-Elect, Guest Editor for “Cell and Gene Therapy Insights’ spotlight on CAR-T Cell Manufacture and Clinical Development”
Click here to view articles from the spotlight on CAR-T Cell Manufacture and Clinical Development
|BioInsights – Interview with Lizette Caballero, ISCT Global Secretary –The Evolution of Product Transfer and Labeling in Cellular Therapy|
Lizette Caballero, Senior Supervisor at UCSF’s Blood and Marrow Transplant Laboratory talks about the impact of compliance with the International Society of Blood Transfusion 128 consensus standards for product labeling. Hear about how the new processes were installed and validated, as well as her vision for updated guidelines on labeling and coding for CAR-T cells in the future.
Lizette Caballero, BS, MT(ASCP)
ISCT Global Secretary
|ASSOCIATE EDITOR Russell Cruz,|
Special thanks to
Wouter Van’t Hof for his assistance in editing this issue.
Wouter Van’t Hof,